NY-APTORUM-GROUP
24.2.2020 12:02:08 CET | Business Wire | Press release
Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary supplement for women undergoing menopause and experiencing related symptoms. The supplement is made with the bioactive ingredient extracted Chinese yam powder containing “DOI”, which is Aptorum Group’s non-hormonal approach intended to meet certain growing consumer nutritional trends and concerns. It is estimated that 1.2 billion women worldwide will be menopausal or postmenopausal by the year 20301 . The global woman’s health supplement market for menopausal symptoms is projected to reach over USD$50bn by 2025 with a CAGR rate of 16.4% (2016-2025)2 . Initially, the supplement will be commercialized and sold in Hong Kong; the Company is seeking regulatory clearance to market the product in other major jurisdictions.
As part of the commercialization, Aptorum Group, through its wholly-owned subsidiary Nativus Life Sciences Limited, entered into a regional distribution agreement with Multipak Limited, a Hong Kong based group that operates household brands, including the Luk Yu® tea bag and other health related products.
Through Multipak, Aptorum Group will be able to increase the accessibility of the product to a large consumer base regionally. The production of Aptorum Group’s dioscorea opposita bioactive nutraceutical tablets has commenced production in Canada and will soon be marketed under the brand name NativusWellTM .
Nativus’s NativusWellTM tablets are natural, non-hormonal supplements containing DOI. The yam powder with DOI utilizes a non-hormonal approach that is intended to boost the general wellness of women undergoing menopause. Third party scientific studies indicate that DOI, the naturally occurring bioactive ingredient in Chinese yam, appears to stimulate estradiol biosynthesis, induce estradiol and progesterone secretion and increase bone density, thereby potentially counteracting the progression of osteoporosis3 , one of the common symptoms associated with menopause4 .
For further general presentation, please visit: http://ir.aptorumgroup.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16
For further technical presentation, please visit: http://ir.aptorumgroup.com/static-files/66346f79-7a03-474a-89be-0eaafaa00d9d
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com .
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 World Health Technical Report Series. Research on the Menopause in the 1990's. Geneva, Switzerland: World Health Organization; 1996.
2 https://www.grandviewresearch.com/press-release/global-isoflavones-market
3 https://www.ke.hku.hk/story/innovation/the-magic-of-chinese-yam-for-treatment-of-menopausal-syndrome ; see also, Scientific Reports, 5-10179.
4 https://www.everydayhealth.com/menopause/osteoporosis-and-menopause.aspx
View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005232/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine10.2.2026 14:00:00 CET | Press release
Financing round led by RA Capital ManagementProceeds to support Phase 3 development of BPZE1 with pivotal study to begin in 2026 ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Series B financing. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharmaceutical company and AI Life Sciences. As part of the financing, Mario Barro, Ph.D., Head of Infectious Diseases at RA Capital Management has joined ILiAD’s Board of Directors. Proceeds from the Series B financing will support the advancement of ILiAD’s next generation pertussis vaccine candidate, BPZE1. Inducing both systemic and mucosal immunity, BPZE1 is a live attenuated intranasal pertussis vac
Armis Launches Armis Centrix™for Application Security to Secure the Code that Runs Organizations10.2.2026 14:00:00 CET | Press release
Solution helps security teams reduce cyber risk exposure, operate more efficiently and streamline their security stack Armis, the cyber exposure management & security company, today announced Armis CentrixTM for Application Security, which unifies application security across an organization’s software development lifecycle. The technology helps security teams secure code as a next-generation attack vector to fortify organizations’ defenses and protect against cyber threats. “To effectively manage risk, it’s essential to get to the root cause of the problem and weed it out,” said Nadir Izrael, CTO and Co-Founder of Armis. “Code-based vulnerabilities are being embedded into organizational infrastructure, and AI-generated code is exacerbating the problem, containing exponentially more vulnerabilities when compared to code written by human developers. As enterprises embrace AI-assisted coding and drive continuous development pipelines, they need a smarter, more dynamic, and unified approac
Sam Elbeck of ExaGrid Honored as a 2026 CRN® Channel Chief10.2.2026 14:00:00 CET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (creating a tiered air gap), delayed deletes and immutability for ransomware recovery,today announced that CRN®—a brand of The Channel Company—has selected Sam Elbeck, ExaGrid’s Vice President of Americas Sales and Channel Partners, for inclusion on the prestigious 2026 CRN® Channel Chiefs list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. “It’s an honor to be named to the Channel Chiefs list again this year,” said Sam Elbeck. “We are committed to the channel and view our partners as an extension of ExaGrid. We collaborate closely on every opportunity to ensure mutual success. Our channel philosophy centers on building long-term relationships grounded in honesty, integrity, and transparency. We strive for ExaGrid to be known a
Vasion Appoints Scott Lee as Chief Product Officer to Accelerate the Impact of Intelligent Print Automation10.2.2026 14:00:00 CET | Press release
Seasoned enterprise product leader brings proven track record of scaling product organizations and driving exponential value Vasion, a leader in serverless printing and Intelligent Print Automation, today announced the appointment of Scott Lee as Chief Product Officer. Lee brings more than 25 years of C-level product and growth leadership experience transforming and scaling enterprise SaaS companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210803525/en/ Scott Lee joins Vasion as Chief Product Officer, bringing more than 25 years of enterprise SaaS leadership experience to accelerate the company's intelligent print automation platform and AI-ready capabilities. As Chief Product Officer at Vasion, Lee will lead product management, product design, and product operations. He will focus on expanding strong product foundations and ensuring customer value as the company scales. His extensive experience modernizing complex
Kingswood Capital Management Enters Into a Definitive Agreement to Acquire Coveris’ Paper Unit, Rebrands as Paragon Print and Packaging10.2.2026 13:00:00 CET | Press release
Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) announced today that it has entered into a definitive agreement to acquire Business Unit Paper (“BU Paper”) from Coveris, a global manufacturer of paper and plastic packaging solutions. As part of the transaction, BU Paper will be rebranded Paragon Print and Packaging (“Paragon”), restoring the unit’s original name. Jo Ormrod, Chief Operating Officer, will serve as Paragon’s Chief Executive Officer, and the existing company management will remain in place. The transaction is expected to close in several weeks, subject to customary legal and regulatory requirements. Paragon produces high-quality, sustainable paper-based packaging solutions, including for key end markets such as food, household, and personal care. The company, which was established in 1994, specializes in products like self-adhesive and linerless labels, lined board, cartons, and trays using eco-friendly materials. “We are excited about our next
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom